流感藥物市場 - 藥物類型、流感類型、年齡層、給藥途徑、類型、藥物、配銷通路、全球預測

由於全球流感感染發生率不斷增加，預計 2024 年至 2032 年間流感藥物市場規模的複合年成長率為 2.9%。根據世界衛生組織的數據，每年約有 10 億例季節性流感病例，其中 300-500 萬例被歸類為重症。隨著全球人口的不斷成長，流感病毒的傳播變得越來越普遍，進一步需要有效的藥物來控制和治療這種疾病。醫療保健專業人員和患者對流感早期診斷和治療重要性的認知不斷提高，這將推動產品需求。

近年來，人們不斷努力開發療效增強、副作用較少的新型抗病毒藥物，並引入創新的給藥方法，例如靜脈注射和鼻內製劑。針對不同流感病毒株的疫苗的開發以及政府和醫療機構為降低流感感染的發生率和嚴重程度而採取的疫苗接種活動也將刺激市場成長。

流感藥物產業分為藥物類型、流感類型、年齡層、給藥途徑、類型、用藥、配銷通路和區域。

根據給藥途徑，靜脈注射領域的市場佔有率預計在 2024 年至 2032 年期間將實現 1.3% 的成長率，因為它能夠將藥物直接輸送到血液中，同時確保藥物的快速有效吸收。這種給藥途徑在嚴重流感感染或口服藥物不可行的情況下特別有利，因為它可以確保立即和有針對性的治療。靜脈注射也使醫療保健專業人員能夠密切監測患者對藥物的反應，並根據需要調整劑量，以提高治療效果並降低併發症的風險。

根據配銷通路，到 2032 年，線上藥局領域的流感藥物市場將以 4.5% 的複合年成長率成長，這得益於其便利性、可及性和成本效益。隨著醫療保健需求越來越依賴數位平台，消費者開始轉向線上藥局，在家中舒適地購買流感藥物。線上藥局能夠比較價格、取得多種產品並在短時間內接受送貨上門的服務，這使得線上藥局成為尋求及時治療流感症狀的個人的一個有吸引力的選擇。

亞太地區流感藥物產業預計將產生利潤豐厚的機會，並在 2024 年至 2032 年期間以 3.6% 的複合年成長率擴張。這可以歸因於各國政府和醫療機構為應對流感疫情而提高的認知和採取的積極措施，特別是在中國和印度等人口稠密的國家。醫療保健基礎設施發展的興起，加上醫療技術和藥品製造能力的進步，將進一步推動該地區的市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 流感盛行率增加
    • 提高對流感藥物的認知與採用
    • 增加與流感藥物相關的研發活動
  • 產業陷阱與挑戰
    • 與抗病毒藥物相關的副作用
    • 與藥物開發相關的高成本
• 成長潛力分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2018 - 2032

• 主要趨勢
• 抗病毒藥物
  • 單一抗病毒藥物
  • 聯合抗病毒藥物
• 抗組織胺藥
• 止痛藥
• 退燒藥

第 6 章：市場估計與預測：按流感類型，2018 年 - 2032 年

• 主要趨勢
• 甲型流感
• 乙型流感

第 7 章：市場估計與預測：按年齡分類，2018 年 - 2032 年

• 主要趨勢
• 成年人
• 兒科
• 老年科

第 8 章：市場估計與預測：按管理途徑，2018 - 2032 年

• 主要趨勢
• 口服
• 吸入
• 靜脈

第 9 章：市場估計與預測：按類型，2018 - 2032

• 主要趨勢
• 品牌化
• 通用的

第 10 章：市場估計與預測：按藥物分類，2018 - 2032 年

• 主要趨勢
• 處方
• 場外交易

第 11 章：市場估計與預測：按配銷通路分類，2018 年 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 12 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 13 章：公司簡介

• AstraZeneca plc
• BioCryst Pharmaceuticals, Inc.
• Daiichi Sankyo Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Lupin
• NATCO Pharma Limited
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Influenza Medications Market size is projected to witness 2.9% CAGR between 2024 and 2032, owing to increasing incidences of influenza infections worldwide. As per WHO, every year, approximately 1 billion cases of seasonal influenza occur, with 3-5 million instances categorized as severe illness. With the expanding global population, the spread of influenza viruses is becoming more prevalent, further imposing the need for effective medications to manage and treat the illness. The rising awareness among healthcare professionals and patients about the importance of early diagnosis and treatment of influenza will fuel the product demand.

Lately, there have been continuous efforts to develop new antiviral drugs with enhanced efficacy and fewer side effects, along with the introduction of innovative drug delivery methods, such as intravenous and intranasal formulations. The development of vaccines targeting different strains of influenza viruses and the adoption of vaccination campaigns by governments and healthcare organizations for reducing the incidence and severity of influenza infections will also stimulate the market growth.

The influenza medications industry is classified into drug type, influenza type, age group, route of administration, type, medication, distribution channel and region.

Based on route of administration, the market share from the intravenous segment is slated to record 1.3% growth rate during 2024-2032, due to its ability to deliver medications directly into the bloodstream while ensuring rapid and efficient absorption of the drug. This route of administration is particularly advantageous in cases of severe influenza infections or when oral medications are not feasible as it ensures immediate and targeted treatment. IV administration also enables healthcare professionals to closely monitor the patient's response to the medication and adjust the dosage as needed for enhancing treatment outcomes and reducing the risk of complications.

As per distribution channel, the influenza medications market from the online pharmacies segment will grow at 4.5% CAGR through 2032, backed by their convenience, accessibility, and cost-effectiveness. With the increasing reliance on digital platforms for healthcare needs, consumers are turning to online pharmacies to purchase influenza medications from the comfort of their homes. The ability to compare prices, access a wide range of products, and receive doorstep delivery within a short timeframe makes online pharmacies an attractive option for individuals seeking timely treatment for influenza symptoms.

Asia Pacific influenza medications industry is expected to generate lucrative opportunities and expand at a 3.6% CAGR from 2024-2032. This can be attributed to the increasing awareness and proactive measures taken by governments and healthcare organizations to combat influenza outbreaks, particularly in densely populated countries, such as China and India. The rise in healthcare infrastructure development, coupled with advancements in medical technology and drug manufacturing capabilities will further propel the market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of influenza
    • 3.2.1.2 Rising awareness and adoption of influenza medications
    • 3.2.1.3 Increasing research and development activities related to influenza drugs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with antiviral drugs
    • 3.2.2.2 High cost associated with drug development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antiviral drugs
  • 5.2.1 Single antiviral drugs
  • 5.2.2 Combination antiviral drugs
• 5.3 Antihistamines
• 5.4 Analgesics
• 5.5 Antipyretics

Chapter 6 Market Estimates and Forecast, By Influenza Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Influenza A
• 6.3 Influenza B

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Adults
• 7.3 Pediatric
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Inhaled
• 8.4 Intravenous

Chapter 9 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Branded
• 9.3 Generic

Chapter 10 Market Estimates and Forecast, By Medication, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Prescription
• 10.3 OTC

Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 Hospital pharmacies
• 11.3 Retail pharmacies
• 11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 Japan
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 Rest of Asia Pacific
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Rest of Latin America
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 Rest of Middle East and Africa

Chapter 13 Company Profiles

• 13.1 AstraZeneca plc
• 13.2 BioCryst Pharmaceuticals, Inc.
• 13.3 Daiichi Sankyo Company
• 13.4 F. Hoffmann-La Roche AG
• 13.5 GlaxoSmithKline plc
• 13.6 Lupin
• 13.7 NATCO Pharma Limited
• 13.8 Novartis AG
• 13.9 Sanofi
• 13.10 Teva Pharmaceutical Industries Ltd.